X-ZELL launches first Cryophore™ Multiplex Antibody Panels for Cytology
Singapore, March 2026 – X-ZELL is proud to announce the commercial launch of its first line of Cryophore™ multiplex antibody panels.
Previewed at the 2025 International Congress of Cytology, the new product line marks an important milestone in the company’s mission to make multi-channel immunostaining more scalable, reproducible and accessible for cytology laboratories worldwide.
Cryophore™ translates X-ZELL’s patented Cryoimmunostaining™ workflow into a structured panel format that enables the simultaneous visualization of multiple immunomarkers on a single slide while preserving morphology and supporting standardized staining conditions.
Multiplex immunostaining is increasingly recognised for its ability to generate richer diagnostic insight from limited cytology material, particularly in minimally invasive specimens such as serous effusions. Broader adoption, however, has been limited by technical complexity and the need for standardized marker combinations and harmonized workflows. [1]
The Cryophore™ range addresses these challenges by providing proprietary fluorophore-conjugated antibody panels designed for cytology, consolidating complementary markers into pre-configured multiplex sets that reduce variability and streamline interpretation.
“Launching our first Cryophore™ panels represents a key step toward establishing multiplex immunostaining in a standardised panel format for cytology.”
Sebastian Bhakdi, X-ZELL Founder
“Launching our first Cryophore™ panels represents a key step toward establishing multiplex immunostaining in a standardised panel format for cytology,” said Sebastian Bhakdi, Founder of X-ZELL. “After years of development and close collaboration with leading clinical experts, we are proud to begin rolling out the first consensus-designed panels.”
The first Cryophore™ release includes three multiplex panels reflecting marker constellations discussed by an international group of cytopathology experts for effusion cytology. Each combines seven fluorophore-labelled antibodies plus a nuclear counterstain in a single workflow.
PLEURAL FLUID 1 (PF1)
Including GATA3, Calretinin, TTF1, EpCAM, CD45, p40, Synaptophysin – a multiplex marker constellation targeting antigens commonly associated with lung adenocarcinoma, small cell and squamous cell carcinoma, as well as breast and urothelial carcinoma cells encountered in pleural effusions.
PLEURAL FLUID 2 (PF2)
Including NKX3.1, Calretinin, TTF1, EpCAM, CD45, p40, Synaptophysin – a variant of PF1 incorporating NKX3.1, a marker frequently referenced in the evaluation of prostate-derived carcinoma cells.
ASCITIC FLUID (AF)
Including PAX8, SATB2, CK19, EpCAM, CD45, Calretinin, CK7 – a multiplex marker constellation targeting antigens commonly associated with colorectal and other gastrointestinal malignancies encountered in ascitic fluid specimens.
The panels are now available for Research Use Only and are not intended for diagnostic procedures. Additional validation activities and panel releases are ongoing for IVDR certification.
X-ZELL gratefully acknowledges its independent clinical collaborators and advisory experts whose expertise and continued engagement have helped shape this initiative and advance multiplex immunostaining in cytopathology.
—
Media Contact
Sebastian Grote
sebastian.g@x-zell.com
About X-ZELL
X-ZELL is an award-winning medical technology company pioneering the field of next-generation cytology. The company’s mission is to transform cancer diagnostics by fusing novel laboratory technology with digital imaging to detect and visualise individual atypical cells in minimally invasive body liquids and digitize them for instant on-screen analysis. Founded by Y Combinator finalist, Dr Sebastian C.P. Bhakdi, X-ZELL was ranked second-most innovative healthcare start-up in the world in 2020 and has since won the coveted MedTech Innovator APAC competition as well as the Abstract Award at the 2021 European Conference of Cytology.
